| Today's News and Trends | PPM is still relatively common after TAVR, especially among patients with a small aortic annulus. What can be done to minimize the risk of PPM? Does valve type play a role? Researchers explored those questions, and many others. PPM is still relatively common after TAVR, especially among patients with a small aortic annulus. What can be done to minimize the risk of PPM? Does valve type play a role? Researchers explored those questions, and many others. | | |
| Landiolol, sold by AOP Health under the brand name Rapiblyk, is an intravenous treatment designed to start working right away. Landiolol, sold by AOP Health under the brand name Rapiblyk, is an intravenous treatment designed to start working right away. | | |
| The Mediterranean diet, named after the traditional eating habits of Greece and Italy, was once again linked to multiple cardiovascular benefits. The focus of this latest meta-analysis was adults over the age of 60. The Mediterranean diet, named after the traditional eating habits of Greece and Italy, was once again linked to multiple cardiovascular benefits. The focus of this latest meta-analysis was adults over the age of 60. | | |
| | The pressure changes associated with contrast injections are minimal, researchers noted, especially once you move away from the tip of the catheter. The pressure changes associated with contrast injections are minimal, researchers noted, especially once you move away from the tip of the catheter. | | |
| Abbott already has an FDA-approved self-expanding TAVR valve, the Navitor system, on the market. The company is now evaluating the safety and effectiveness of a new balloon-expandable device that could potentially be implanted using software guidance. Abbott already has an FDA-approved self-expanding TAVR valve, the Navitor system, on the market. The company is now evaluating the safety and effectiveness of a new balloon-expandable device that could potentially be implanted using software guidance. | | |
| Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures. Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures. | | |
| | Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more. Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more. | | |
| Researchers took a closer look at the effectiveness of redo TAVR, implanting Sapien 3 valves into a variety of explanted CoreValve and Evolut valves. Researchers took a closer look at the effectiveness of redo TAVR, implanting Sapien 3 valves into a variety of explanted CoreValve and Evolut valves. | | |
| The new data, presented during AHA Scientific Sessions 2024, suggest LAAC with Boston Scientific's Watchman FLX could be a safe, effective alternative to OAC for limiting post-ablation strokes. The new data, presented during AHA Scientific Sessions 2024, suggest LAAC with Boston Scientific's Watchman FLX could be a safe, effective alternative to OAC for limiting post-ablation strokes. | | |
| | Hospitals and physicians are pressing lawmakers to pass two previously proposed pieces of legislation that allow international medical graduates to work here longer. Hospitals and physicians are pressing lawmakers to pass two previously proposed pieces of legislation that allow international medical graduates to work here longer. | | |
| The startup, which offers cloud-based software that integrates disparate elements of a rad's workflow, also named a new CEO. The startup, which offers cloud-based software that integrates disparate elements of a rad's workflow, also named a new CEO. | | |
| |
|
| ![]() | |
|
![Left atrial appendage occlusion (LAAO) with the Watchman FLX device from Boston Scientific is associated with positive outcomes and limited adverse events after one year, according to new findings published in Circulation: Cardiovascular Interventions.[1] Many prior Watchman FLX studies, including PINNACLE FLX, had focused on the device’s performance in a controlled setting. The study’s authors hoped to gain a better understanding of its real-world impact by reviewing registry data from more than 97,000 U.S](https://cardiovascularbusiness.com/sites/default/files/styles/media_thumbnail/public/2024-08/screenshot_2024-08-12_at_11.35.13_am.png?itok=GxbuOU6H)
